The startup develops TRPC inhibitors aimed at treating metabolic diseases and cardiac conditions by creating novel lead compounds in collaboration with academic institutions. These medicines target obesity and pathological remodeling, providing the healthcare industry with new therapeutic options.
Funding
Funding not disclosed
Founders
Product
Problem
Current treatments for metabolic diseases and pathological cardiac remodeling have limitations in addressing the underlying mechanisms, leading to suboptimal outcomes. Specifically, there is a need for more targeted therapies that can effectively modulate calcium signaling pathways involved in these conditions. Obesity and cardiac hypertrophy, key features of these diseases, require novel therapeutic interventions.
Solution
CalTIC GmbH is developing a new class of medicines based on Transient Receptor Potential Channel (TRPC) inhibitors to treat metabolic diseases and pathological cardiac remodeling. Their approach focuses on generating novel lead compounds that selectively target TRPC proteins, which are genetically validated targets for these conditions. By inhibiting TRPC channels, CalTIC aims to modulate calcium entry into cells, thereby preventing pressure overload-induced hypertrophy and interstitial fibrosis in cardiac hypertrophy, as well as addressing the underlying mechanisms of obesity. The company collaborates with academic institutions and the Lead Discovery Center GmbH to identify and optimize these novel inhibitors.
Target Audience
The primary target audience includes patients suffering from metabolic diseases such as obesity, as well as individuals with pathological cardiac remodeling and cardiac hypertrophy.
Features
- Development of small molecule inhibitors targeting TRPC proteins.
- Focus on TRPC inhibition to modulate calcium signaling in cardiomyocytes and other relevant cell types.
- Lead compound generation with in vivo proof-of-concept and lead optimization potential.
- Collaboration with leading academic institutions for target validation and drug discovery.
- Addressing both metabolic disease/obesity and pathological cardiac remodeling with a single therapeutic approach.